Development of a novel system for estimating human intestinal absorption using caco-2 cells in the absence of esterase activity

Drug Metabolism and Disposition

Volumn 38, Issue 2, 2010, Pages 323-331

  Ohura, Kayoko ^a   Sakamoto, Hisae ^a   Ninomiya, Shin Ichi ^b   Imai, Teruko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SEKISUI CHEMICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIS 4 NITROPHENYLPHOSPHATE; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; DRUG METABOLIZING ENZYME; ETHYLFEXOFENADINE; FEXOFENADINE; O BUTYRYLPROPRANOLOL; PRODRUG; PROPRANOLOL DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN CACO 2; CELL TRANSPORT; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DIFFUSION; DRUG HYDROLYSIS; DRUG PENETRATION; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; INTESTINE ABSORPTION; PRIORITY JOURNAL; SMALL INTESTINE;

BIOLOGICAL TRANSPORT; CACO-2 CELLS; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CELL MEMBRANE PERMEABILITY; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; ESTERS; HUMANS; INTESTINAL ABSORPTION; NITROPHENOLS; PRODRUGS; PROPRANOLOL; TERFENADINE;

EID: 76149095624     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.029413     Document Type: Article

References (40)

1. Artursson P, Palm K, and Luthman K (2001) Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46:27-43.
2. 14C] phenylphosphate as carboxylesterases and amidases. Biochim Biophys Acta 524:85-93.
3. Borlak J and Zwadlo C (2003) Expression of drug-metabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells. Xenobiotica 33:927-943.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Choi W, Cogdell D, Feng Y, Hamilton SR, and Zhang W (2006) Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway. Cancer Biol Ther 5:1450-1456.
6. Di Giacomo B, Coletta D, Natalini B, Ni MH, and Pellicciari R (1999) A new synthesis of carboxyterfenadine (fexofenadine) and its bioisosteric tetrazole analogs. Farmaco 54:600-610.
7. Gartel AL, Feliciano C, and Tyner AL (2003) A new method for determining the status of p53 in tumor cell lines of different origin. Oncol Res 13:405-408.
8. Gotoh S, Nakamura R, Nishiyama M, Quan YS, Fujita T, Yamamoto A, and Muranishi S (1996) Effects of protease inhibitors on the absorption of phenol red and fluorescein isothiocyanate dextrans from the rat intestine. J Pharm Sci 85:858-862.
9. Gram LK, Rist GM, Lennernäs H, and Steffansen B (2009) Impact of carriers in oral absorption: permeation across Caco-2 cells for the organic anions estrone-3-sulfate and glipizide. Eur J Pharm Sci 37:378-386.
10. Grès MC, Julian B, Bourrié M, Meunier V, Roques C, Berger M, Boulenc X, Berger Y, and Fabre G (1998) Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm Res 15:726-733.
11. Heymann E and Krisch K (1967) Phosphoric acid-bis-(p-nitro- phenylester), a new inhibitor of microsomal carboxylesterases. Hoppe Seylers Z Physiol Chem 348:609-619.
12. Hidalgo IJ and Li J (1996) Carrier-mediated transport and efflux mechanisms in Caco-2 cells. Adv Drug Deliv Rev 22:53-66.
13. Imai T (2006) Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173-185.
14. Imai T, Imoto M, Sakamoto H, and Hashimoto M (2005) Identification of esterases expressed in Caco-2 cells and effects of their hydrolyzing activity in predicting human intestinal absorption. Drug Metab Dispos 33:1185-1190.
15. Jeong EJ, Liu Y, Lin H, and Hu M (2005) Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 33:785-794.
16. Kamath AV, Morrison RA, Harper TW, Lan SJ, Marino AM, and Chong S (2005) Multiple pathways are involved in the oral absorption of BMS-262084, a tryptase inhibitor, in rats: role of paracellular transport, binding to trypsin, and P-glycoprotein efflux. J Pharm Sci 94:1115-1123.
17. Machida M, Hayashi M, and Awazu S (2000) The effects of absorption enhancers on the pulmonary absorption of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Biol Pharm Bull 23:84-86.
18. Masaki K, Hashimoto M, and Imai T (2007) Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum. Drug Metab Dispos 35:1089-1095.
19. Masaki K, Taketani M, and Imai T (2006) First-pass hydrolysis of a propranolol ester derivative in rat small intestine. Drug Metab Dispos 34:398-404.
20. Mentlein R, Rix-Matzen H, and Heymann E (1988) Subcellular localization of non-specific carboxylesterases, acylcarnitine hydrolase, monoacylglycerol lipase and palmitoyl-CoA hydrolase in rat liver. Biochim Biophys Acta 964:319-328.
21. Nakamura T, Sakaeda T, Ohmoto N, Tamura T, Aoyama N, Shirakawa T, Kamigaki T, Nakamura T, Kim KI, Kim SR, et al. (2002) Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos 30:4-6.
22. Nishimura M, Yoshitsugu H, Naito S, and Hiraoka I (2002) Evaluation of gene induction of drug-metabolizing enzymes and transporters in primary culture of human hepatocytes using high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 122:339-361.
23. Okudaira N, Komiya I, and Sugiyama Y (2000) Polarized efflux of mono- and diacid metabolites of ME3229, an ester-type prodrug of a glycoprotein IIb/IIIa receptor antagonist, in rat small intestine. J Pharmacol Exp Ther 295:717-723.
24. Perloff MD, von Moltke LL, and Greenblatt DJ (2002) Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 42:1269-1274.
25. Pinto M, Robine-Leon S, Appay MD, Kedinger M, Triadou N, Dussaulx E, Lacroix B, Simmon-Assmann P, Haffen K, Fogh J, et al. (1983) Enterocyte-like differentiation and polarization of the human colon carcinoma cell line Caco-2 in culture. Biol Cell 47:323-330.
26. Raeissi SD, Hidalgo IJ, Segura-Aguilar J, and Artursson P (1999) Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 16:625-632.
27. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, and La Du BN (2002) Current progress on esterases: from molecular structure to function. Drug Metab Dispos 30:488-493.
28. Seithel A, Karlsson J, Hilgendorf C, Björquist A, and Ungell AL (2006) Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur J Pharm Sci 28:291-299.
29. Shameem M, Imai T, and Otagiri M (1993) An in-vitro and in-vivo correlative approach to the evaluation of ester prodrugs to improve oral delivery of propranolol. J Pharm Pharmacol 45:246-252.
30. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, Akhlaghi F, and Yan B (2006) Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther 319:1477-1484.
31. Siissalo S, Zhang H, Stilgenbauer E, Kaukonen AM, Hirvonen J, and Finel M (2008) The expression of most UDP-glucuronosyltransferases (UGTs) is increased significantly during Caco-2 cell differentiation, whereas UGT1A6 is highly expressed also in undifferentiated cells. Drug Metab Dispos 36:2331-2336.
32. Sun D, Lennernas H, Welage LS, Barnett JL, Landowski CP, Foster D, Fleisher D, Lee KD, and Amidon GL (2002) Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res 19:1400-1416.
33. Tabata T, Katoh M, Tokudome S, Nakajima M, and Yokoi T (2004) Identification of the cytosolic carboxylesterase catalyzing the 5́-deoxy-5-fluorocytidine formation from capecitabine in human liver. Drug Metab Dispos 32:1103-1110.
34. Takai S, Matsuda A, Usami Y, Adachi T, Sugiyama T, Katagiri Y, Tatematsu M, and Hirano K (1997) Hydrolytic profile for ester- or amide-linkage by carboxylesterases pI 5.3 and 4.5 from human liver. Biol Pharm Bull 20:869-873.
35. Tang M, Mukundan M, Yang J, Charpentier N, LeCluyse EL, Black C, Yang D, Shi D, and Yan B (2006) Antiplatelet agents aspirin and clopidogrel are hydrolyzed by distinct carboxylesterases, and clopidogrel is transesterificated in the presence of ethyl alcohol. J Pharmacol Exp Ther 319:1467-1476.
36. Tsuji A and Tamai I (1996) Carrier-mediated intestinal transport of drugs. Pharm Res 13:963-977.
37. Wadkins RM, Hyatt JL, Wei X, Yoon KJ, Wierdl M, Edwards CC, Morton CL, Obenauer JC, Damodaran K, Beroza P, et al. (2005) Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. J Med Chem 48:2906-2915.
38. Watkins PB (1997) The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170.
39. Wu MH, Chen P, Remo BF, Cook EH Jr, Das S, and Dolan ME (2003) Characterization of multiple promoters in the human carboxylesterase 2 gene. Pharmacogenetics 13:425-435.
40. Yamashita S, Tanaka Y, Endoh Y, Taki Y, Sakane T, Nadai T, and Sezaki H (1997) Analysis of drug permeation across Caco-2 monolayer: implication for predicting in vivo drug absorption. Pharm Res 14:486-491.